Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor

NCT01267695 | Completed Phase 2 DMC

• 1 other identifier: WJP-320.6700.09010
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Perioperative imatinib mesylate may shrink the tumor and may reduce the chance of relapse after surgery. This phase II trial is studying the effectiveness of perioperative imatinib mesylate in treating patients with locally advanced gastrointestinal stromal tumor.

Conditions

Gastrointestinal Stromal Tumor

Keywords

Gastrointestinal Stromal Tumor; Imatinib mesylate; Perioperative therapy

Outcome Measures

Primary Outcomes (1)

• Rate of disease recurrence at 2 years

  4 years

Secondary Outcomes (2)

• Rates of objective response (complete, partial, and stable)

  2 years

• Determine the safety and tolerability of this drug in these patients.

  3 years

Interventions

imatinib mesylate DRUG

Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.

Also known as: Gleevec, STI-571, NSC #716051

conventional surgery PROCEDURE

All the patients should receive elective surgery with R0 resection.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

Criteria: * DISEASE CHARACTERISTICS: * Histologically confirmed gastrointestinal stromal tumor * Locally advanced disease: tumour size \>5 cm and mitotic count \>5/HPF; tumour size \>10 cm; mitotic count \>10/HPF * Potentially resectable disease: Multivisceral resection may be necessary to get sufficient margins * Documented c-kit (CD117) expression by immunohistochemical analysis of either initial core specimen or, if recurrent disease, from original tumor block * At least 1 site of measurable disease * No known brain metastases * PATIENT CHARACTERISTICS: Age:18 and over Performance status:ECOG 0-3 Life expectancy:Not specified * Platelet count \> 100,000/mm3 * Absolute neutrophil count \> 1,500/mm3 Hepatic * AST and ALT \< 2.5 times upper limits of normal (ULN) (5 times ULN if hepatic metastases are present) * Bilirubin \< 1.5 times ULN * No chronic active hepatitis * No cirrhosis * No other chronic liver disease Renal * Creatinine \< 1.5 times ULN * No chronic renal disease Cardiovascular * No New York Heart Association class III-IV cardiac disease * No congestive heart failure * No myocardial infarction within the past 6 months Immunology * No active uncontrolled infection * No known HIV positivity Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment * Must be medically fit to undergo surgery * No other primary malignancy within the past 5 years except basal cell skin cancer, carcinoma in situ of the cervix, or a primary malignancy that is not currently clinically significant and does not require active intervention * No gastrointestinal obstruction or major bleeding episode requiring immediate surgical intervention * No uncontrolled diabetes * No other severe or uncontrolled medical disease * No significant history of noncompliance to medical regimens PRIOR CONCURRENT THERAPY: * No concurrent anticancer biologic agents * More than 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) unless disease is rapidly progressing * No concurrent anticancer chemotherapy * At least 28 days since prior radiotherapy * More than 2 weeks since prior major surgery except tumor biopsy Other * At least 28 days since prior investigational drugs * At least 28 days since prior imatinib mesylate * No concurrent therapeutic doses of warfarin * Concurrent low-molecular weight heparin or mini-dose warfarin (1 mg per day) prophylaxis is allowed

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Peking University: lead

Study Sites (1)

Peking University School of Oncology

Beijing, 100142, China

Location

Related Publications (4)

• Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009 Jan 1;99(1):42-7. doi: 10.1002/jso.21160.

  PMID: 18942073 BACKGROUND

• Seshadri RA, Rajendranath R. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors. J Cancer Res Ther. 2009 Oct-Dec;5(4):267-71. doi: 10.4103/0973-1482.59905.

  PMID: 20160360 BACKGROUND

• Saied GM, Kensarah AM. Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients. Int J Surg. 2010;8(2):105-8. doi: 10.1016/j.ijsu.2009.09.016. Epub 2009 Nov 24.

  PMID: 19944196 BACKGROUND

• Machlenkin S, Pinsk I, Tulchinsky H, Ziv Y, Sayfan J, Duek D, Rabau M, Walfisch S. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. Colorectal Dis. 2011 Oct;13(10):1110-5. doi: 10.1111/j.1463-1318.2010.02442.x.

  PMID: 21040362 BACKGROUND

Related Links

• Related Info

MeSH Terms

Conditions

Gastrointestinal Stromal Tumors

Interventions

Imatinib Mesylate

Condition Hierarchy (Ancestors)

Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases

Intervention Hierarchy (Ancestors)

Benzamides; Amides; Organic Chemicals; Benzoates; Acids, Carbocyclic; Carboxylic Acids; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Piperazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrimidines

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: vice director of Department of Gastrointestinal Surgery，Peking University Cancer Hospital and Institute

Study Record Dates

• First Submitted: December 27, 2010
• First Posted: December 28, 2010
• Study Start: May 1, 2010
• Primary Completion: October 1, 2014
• Study Completion: October 1, 2014
• Last Updated: February 3, 2015

Record last verified: 2015-02

Locations

CN (1)